PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: IPAB
Obamacare After Nov 6th: Trouble for Pharma?
by Tom Norton
No doubt the November 6th election is going to be close, very close: close for the Presidency, close for the Senate, and possibly close for the House. So close, in fact, it’s possible that no substantial political change will occur in Washington, as a result.
That said, for the U.S. pharmaceutical industry this is [...]
Posted in Events, FDA, Legal, Market Access, R&D, Regulatory, leadership, pricing Also tagged ACOs, CER, Obamacare, PCORI 3 Comments
Fixing Innovation: Lilly's CEO Says Why, and How
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing Also tagged CEO, CEOs, drug safety, Eli Lilly, Financial Times, Global, healthcare reform, innovation, IP, Lilly, PhRMA, policy, R&D 1 Comment
IPAB : An HCR Acronym You Need to Understand
Tom Norton throws some light on the much-vaunted Independent Payment Advisory Board.
Working towards our top issue for the June edition of the HCR Monthly Review, I continue to be struck by the amount of macroeconomic data that will be driving the new HCR law. Indeed, most of the key performance measures in the 2010 statute [...]
Posted in Regulatory, healthcare Also tagged HCR, healthcare reform, Independent Payment Advisory Board, Medicaid, Medicare, NICE 2 Comments
Questions About the 2013 Implementation of IPAB